ATAI Life Sciences NV
ATAIToday
+0.82%
5 Days
0.00%
1 Month
-0.14%
6 Months
+105.88%
Year to Date
+79.71%
1 Year
+48.48%
Key Figures
• Amgen's growth is driven by its metabolic disease pipeline and obesity candidate progress. • Robust oncology and inflammation sales support the company's updated revenue outlook. • Technical indicators show a neutral market signal with a bearish overall sentiment index.
• Positive clinical trial outcomes for Skyrizi and Rinvoq bolster AbbVie’s post-Humira growth strategy. • Institutional investors favor AbbVie for its robust dividend profile and resilient cash flows. • Investment banks recently raised long-term forecasts citing improved margins and reduced pricing concerns.
• Merck shares rose due to oncology pipeline progress and portfolio diversification. • Analysts increased price targets following strong vaccine and animal health performance. • Technical indicators show a neutral market signal with an RSI of 51.947.
ATAI Life Sciences NV's Score
Media Coverage
Analyst Rating
ATAI Life Sciences NV Technical Analysis
Technical Indicators
Summary
Moving Average
Financial Indicators
Earnings
ATAI Life Sciences NV Profile
Ownership
| Shareholders | Proportion |
|---|---|
| Apeiron Investment Group Ltd | 15.00% |
| Vanguard Capital Management, LLC | 3.19% |
| Feilding-Mellen (Cosmo) | 2.08% |
| Adage Capital Management, L.P. | 1.92% |
| Shareholder Types | Proportion |
|---|---|
| Family Office | 15.07% |
| Investment Advisor | 9.87% |
| Hedge Fund | 6.24% |
| Investment Advisor/Hedge Fund | 4.50% |
Related Instruments
Popular Instruments
